IL-17A和ER蛋白在子宫内膜癌组织中的表达水平及对患者预后的预测价值

doi:10.3969/j.issn.1671-7171.2022.09.016

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1727 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate expression and prognostic significance of interleukin-17A (IL-17A) and Estrogen receptor (ER) proteins in endometrial carcinoma (EC). 【Methods】A prospective study was conducted in 89 EC patients admitted to Xi'an International Medical Center Hospital from May 2013 to August 2016. All patients underwent surgical resection and were followed up for 5 years after surgery. Immunohistochemistry was used to detect the expression of IL-17A and ER proteins. The expression of IL-17A and ER protein in cancer tissues and adjacent tissues were compared. The relationship of clinicopathological parameters with expression of IL-17A and ER proteins in EC patients was analyzed. Factors affecting the prognosis of EC patients were analyzed. The relationship between IL-17A and ER protein expression in cancer tissues and survival of EC patients was analyzed as well. 【Results】Eleven patients were lost to follow-up by the end of follow-up. The positive expression rate of IL-17A in cancer tissues was higher than adjacent tissues (P<0.05), and the positive expression rate of ER was lower than adjacent tissues (P<0.05). Positive expression rate of IL-17A in cancer tissues of patients with low differentiation, invasion depth ≥1/2, stage Ⅲ and vascular cancer thrombus was higher than that of patients with medium and high differentiation, invasion depth < 1/2, stage Ⅰ~Ⅱ and no vascular carcinoma thrombus (P<0.05). Positive expression rate of ER protein in cancer tissues of patients with low differentiation, invasion depth ≥1/2, stage Ⅲ and complicated with vascular tumor thrombus was lower than that of patients with medium and high differentiation, invasion depth <1/2, stage Ⅰ~Ⅱ and no complicated vascular tumor thrombus (P<0.05). Cox regression analysis showed that the degree of differentiation, surgical pathological stage, vascular tumor thrombus, positive IL-17A and positive ER expression were independent prognostic factors affecting EC recurrence (P<0.05). Tumor differentiation degree, surgical pathological stage, positive IL-17A and positive ER expression were independent prognostic factors affecting the overall survival rate (P<0.05). There were 37 disease-free patients with positive IL-17A and 25 disease-free patients with negative IL-17A; And the difference in disease-free survival curve between patients with positive IL-17A expression and patients with negative IL-17A expression was statistically significant (P<0.05).Forty-four patients with positive IL-17A survived, and 26 patients with negative IL-17A survived. There was no significant difference in the overall survival curve between patients with positive IL-17A expression and patients with negative IL-17A expression (P>0.05). There were 36 disease-free patients in ER positive patients and 26 disease-free patients in ER negative patients. The difference in disease-free survival curves between ER positive and negative patients was statistically significant (P<0.05). There were 39 ER positive patients survived and 31 ER negative patients survived; And the overall survival curve of ER positive and negative patients was statistically significant (P<0.05). 【Conclusion】Expression of IL-17A and ER protein in EC patients' cancer tissues is related to clinicopathological parameters and prognosis. Patients with IL-17A positive and ER negative have a high risk of poor prognosis.

Key words： Endometrial Neoplasms/PA Interleukin-17 Receptors,Estrogen Prognosis

Received: 15 March 2022

PACS:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Li
	HUI Hui

Cite this article:

WANG Li,HUI Hui. Expression and Prognosis Predictive Value of IL-17A and ER Proteins in Endometrial Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(9): 1336-1340.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.09.016 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I9/1336

[1] URICK M E,BELL D W.Clinical actionability of molecular targets in endometrial cancer[J].Nat Rev Cancer,2019,19(9):510-521.
[2] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):501-512.
[3] 沈伟娟,张溢.外周静脉血肿瘤异常蛋白检测对乳腺癌患者的疗效监测及评估价值[J].医学临床研究,2021,38(4):508-511.
[4] 王丽华,张璇,王亮亮,等.IL-17A/IL-17RA通过上调自噬降低卵巢癌SKOV3细胞对顺铂敏感性[J].南方医科大学学报,2020,40(11):20-26.
[5] 陈宏.白细胞介素-17A在宫颈癌中的表达及其与肿瘤血管生成之间的关系[J].武汉大学学报,2018,39(6):930-934.
[6] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(8):52-58.
[7] 赵涛,宋玉霞,张宏煜,等.绝经后子宫内膜癌合并感染对HE4和VEGF及炎症因子水平的影响[J].中华医院感染学杂志,2019,29(15):131-135.
[8] CROSBY D A,GLOVER L E,BRENNAN E P,et al.Dysregulation of the interleukin-17A pathway in endometrial tissue from women with unexplained infertility affects pregnancy outcome following assisted reproductive treatment[J].Hum Reprod,2020,35(8):1875-1888.
[9] 宋扬,廖予妹.年轻患者子宫内膜癌组织中ER,PR,P53病理表达情况及其临床意义[J].中国现代医学杂志,2017,27(16):49-52.
[10] KOZAR N,KRUUSMAA K,DOVNIK A,et al.Identification of novel diagnostic biomarkers in endometrial cancer using targeted metabolomic profiling[J].Adv Med Sci,2021,66(1):46-51.
[11] CHENG R,XUE X,LIU X.Expression of IL-17A in endometrial carcinoma and effects of IL-17A on biological behaviour in Ishikawa cells[J].J Int Med Res,2020,48(9):300060520950563.
[12] 闫美玲,张亚莉,张莉.白细胞介素-17A和白细胞介素-17F在卵巢上皮性癌组织中的表达情况及与患者临床特征的关系[J].癌症进展,2021,19(1):56-58.
[13] VAN WEELDEN W J,VAN DER PUTTEN L J M,INDA M A,et al.Oestrogen receptor pathway activity is associated with outcome in endometrial cancer[J].Br J Cancer,2020,123(5):785-792.